After an overview of HL epidemiology and biology in the AYA population, this review will cover frontline pediatric and adult treatment approaches.
One-Alpha* is indicated in all conditions where there is a disturbance of calcium metabolism due to impaired 1-α hydroxylation such as when there is reduced renal function. The main indications are: a) Renal osteodystrophy b) Hyperparathyroidism (with bone disease) c) Hypoparathyroidism d) Neonatal hypocalcaemia e) Nutritional and malabsorptive rickets and osteomalacia f) Pseudo-deficiency (D-dependent) rickets and osteomalacia g) Hypophosphataemic vitamin D resistant rickets and osteomalacia
Genentech, announced that the Phase III MINISTONE-2 study showed that one-dose Xofluza (baloxavir marboxil) was a well-tolerated and effective potential...
EDAP TMS SA a global leader in therapeutic ultrasound, announced that it has received 510(k) clearance from the FDA for...
Health Canada has granted Vertex Pharmaceuticals’ Orkambi (lumacaftor/ivacaftor) a marketing authorisation for the treatment of cystic fibrosis (CF) for children ages between one and two
Roche announced that The Lancet has published two papers highlighting one-year results from four pivotal phase III studies of faricimab, an investigational bispecific antibody, in neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Ascensia Diabetes Care announced it has received FDA 510(k) clearance for the Contour Next One Blood Glucose Monitoring System (BGMS),...
Daiichi Sankyo Europe announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients, mostly elderly,...
Vertex Pharmaceuticals Incorporated announced Health Canada has granted Marketing Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation.